Deng H, Sun B
Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an.
Zhonghua Nei Ke Za Zhi. 1997;36(1):7-10.
To study the influence of oral glucocorticoid on CD4 T-lymphocyte and eosinophil activation in the asthmatics, we collected the serum samples from 14 patients who required oarl glucocorticoid therapy for moderate to severe disease exacerbations and measured the serum interleukin (IL)-5, eosinophil cationic protein (ECP) levels before and after one week with prednisone (20 mg/d) by enzyme-linked immunosorbent assay. The results revealed that after oral prednisone therapy, the serum IL-5, ECP levels and the numbers of peripheral blood eosinophils decreased, whereas the lung function significantly improved. It is suggested that glucocorticoids might exert antiasthma effect of by inhibiting CD4 T-lymphocyte activation and cytokine (e.g., IL-5) secretion.
为研究口服糖皮质激素对哮喘患者CD4 T淋巴细胞及嗜酸性粒细胞活化的影响，我们收集了14例因中重度病情加重而需口服糖皮质激素治疗的患者的血清样本，并通过酶联免疫吸附测定法检测了使用泼尼松（20mg/d）治疗一周前后血清白细胞介素（IL）-5、嗜酸性粒细胞阳离子蛋白（ECP）水平。结果显示，口服泼尼松治疗后，血清IL-5、ECP水平及外周血嗜酸性粒细胞数量均下降，而肺功能显著改善。提示糖皮质激素可能通过抑制CD4 T淋巴细胞活化及细胞因子（如IL-5）分泌发挥抗哮喘作用。
